Role of heparin in recurrent implantation failures in IVF

Luteal phase low molecular weight heparin in fresh non donor IVF/ICSI cycles in women with previous failed fresh IVF/ICSI cycles - HepRIF

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010176

Enrollment

100

Registered

2017-10-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- INFERTILITY

Interventions

Intervention1: heparin: Those who meet inclusion criteria of the study and receive the drug Inj low molecular weight heparin 1mg/kg/day duration - 6 weeks if UPT negative 36 weeks if U

Eligibility

Inclusion criteria

Inclusion criteria: Women requiring anticoagulant therapy for other medical reasons Obvious causes of implantation failure (hydrosalpinx visible on transvaginal ultrasound, fibroids distorting the uterine cavity, the absence of Grade I or Grade II embryos available for transfer) Clinical or laboratory findings of congenital or acquired thrombophilia. Severe male factor infertility requiring sperm retrievals.

Exclusion criteria

Exclusion criteria: 1.women requiring anticoagulant therapy 2.obvious causes of implantation failure (untreated hydrosalpinx, fibroids, absence of grade 1 or grade 2 embryos available for transfer 3. clinical or laboratory findings of congenital or acquired thrombophilia 4. severe male factor infertility requiring surgical sprem retrievals

Design outcomes

Primary

Measure	Time frame
Implantation rate per embryo transfer clinical pregnancy rateTimepoint: 6 weeks	—

Secondary

Measure	Time frame
Ongoing pregnancy rateTimepoint: 20 weeks	—

Countries

India

Contacts

Public ContactDr Rohitha C

AIIMS

redruby9191@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026